Skip to main content
Hua Medicine logo

Hua Medicine — Investor Relations & Filings

Ticker · 2552 HKEX Manufacturing
Open in API
Filings indexed 296 across all filing types
Latest filing 2026-02-05 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2552

About Hua Medicine

http://www.huamedicine.com

Hua Medicine is an innovative drug development and commercialization company focused on creating novel therapies for patients with unmet medical needs globally. The company specializes in leading innovation in diabetes care. Its core commercialized product is HuaTangNing® (dorzagliatin), a first-in-class Glucokinase Activator (GKA) approved for the treatment of Type 2 Diabetes (T2D). Dorzagliatin functions by targeting the glucose sensor Glucokinase to restore glucose homeostasis and improve glucose sensitivity. A key clinical advantage is its suitability for T2D patients with renal impairment, as it requires no dose adjustment. Beyond diabetes, the company's pipeline includes mGluR5 NAM (Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator), a potential novel treatment for L-Dopa-induced dyskinesia in Parkinson's disease.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Exchanges and Clearing Limited. This specific form is used by companies listed on the HKEX to report monthly movements in securities, including changes in share capital, share options, and treasury shares. This type of filing is a standard regulatory requirement for HKEX-listed companies and falls under the category of share capital changes and regulatory reporting.
2026-02-05 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. Since it is a recurring regulatory filing regarding share capital and securities movements that does not fit into specific categories like 'Share Issue' (which is usually a one-off event) or 'Director's Dealing', it is best classified as a Regulatory Filing (RNS).
2026-01-07 English
VOLUNTARY ANNOUNCEMENT
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from Hua Medicine regarding the progress of a clinical trial (Phase Ib trial of HMS1005). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate update regarding business operations and clinical development that does not fall into a more specific category, it is classified as a Regulatory Filing (RNS).
2025-12-09 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies to report monthly movements in their securities, including share capital, issued shares, and share options. Since it is a recurring regulatory filing regarding share capital and securities movements that does not fit into specific categories like 'Share Issue' (which usually refers to a specific event) or 'Director's Dealing', it is best classified as a general regulatory filing.
2025-12-04 English
GRANT OF SHARE OPTIONS
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement from Hua Medicine regarding the 'Grant of Share Options' to directors and employees. It details the number of options, exercise price, vesting schedule, and performance targets. This type of disclosure regarding the issuance of new share options or capital changes falls under the 'Share Issue/Capital Change' category, as it relates to the potential future issuance of shares and changes to the company's capital structure.
2025-12-01 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 1% confidence The document is a formal announcement titled 'LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS' for Hua Medicine. It lists the current members of the Board of Directors and their respective committee assignments following a change effective November 27, 2025. This type of disclosure regarding board composition and committee structure falls under the 'Board/Management Information' category.
2025-11-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.